Drug Safety and Risk Management Advisory Committee May 18-19, 2005 1 Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

Slides:

Advertisements

Similar presentations

What Is the Role for Analyses of Administrative Data in Assessing Drug Safety in Post-Market Commitment (PMC) Studies? Cathy W. Critchlow, PhD Global Epidemiology,

Advertisements

National Health Policy Conference, Washington, DC February 6, Drug Safety Challenges: Considerations for Sources of Data Gerald J. Dal Pan, MD,

Agency for Healthcare Research and Quality (AHRQ)

Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.

Study Designs in Epidemiologic

Case-Control Studies (Retrospective Studies). What is a cohort?

Elements of a clinical trial research protocol

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release.

Pharmacoepidemiology: Goals and Methods Sean Hennessy, PharmD, PhD Assistant Professor of Epidemiology & Pharmacology Center for Clinical Epidemiology.

Monitoring Safety of Rotavirus Vaccines David Martin, MD, MPH CBER Office of Biostatistics and Epidemiology, FDA For presentation at the Vaccines and Related.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

Interpreting Adverse Signals in Diabetes Drug Development Programs Featured Article: Clifford J. Bailey, Ph.D. Diabetes Care Volume 36: 1-9 July, 2013.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.

Specific Clinical/Regulatory Issues in Development of Drugs for Peripheral Neuropathy and Neuropathic Pain Gerald J. Dal Pan, MD, MHS Medical Officer Division.

DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Accutane FDA (Section Name - Saver’s Initials) 3/9/00 12:50 PM 1 Introduction Russell Ellison, MD Chief Medical Officer Vice President, Medical Affairs.

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 7: Gathering Evidence for Practice.

Cellular Products for Cardiac Diseases Dwaine Rieves, MD Center for Biologics Evaluation and Research FDA Perspective on:

AETIOLOGY Case control studies (also RCT, cohort and ecological studies)

CHP400: Community Health Program- lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Case Control Studies Present: Disease Past:

DSaRM Advisory Committee May 19, 2005 Postmarketing Studies: OND Perspective Julie Beitz MD, Deputy Director, Office of Drug Evaluation III, Office of.

First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP.

Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Types of study designs Arash Najimi

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.

M-CERSI Workshop – Envisioning the Future of Mobile Informatics Division of Postmarket Surveillance 1 Overview I.What DPS does… II.The Brick Model… III.Where.

CDER / CBER Pharmacovigilance Working Group

CAT 3 Harm, Causation Maribeth Chitkara, MD Rachel Boykan, MD.

Population-Based Epidemiologic Safety Studies: Overview and Challenges Drug Safety and Risk Management Advisory Committee Silver Spring, Maryland June.

DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.

METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.

VIOXX ™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001 Lourdes Villalba, M.D. DAAODP, CDER, FDA.

LEADING RESEARCH… MEASURES THAT COUNT Challenges of Studying Cardiovascular Outcomes in ADHD Elizabeth B. Andrews, MPH, PhD, VP, Pharmacoepidemiology and.

Case Control Study: An example Depression and the Risk of Out-of-hospital cardiac arrest July, 2005.

Basic concept of clinical study

Survival Analysis 1 Always be contented, be grateful, be understanding and be compassionate.

FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.

Overview of Study Designs. Study Designs Experimental Randomized Controlled Trial Group Randomized Trial Observational Descriptive Analytical Cross-sectional.

Good Pharmacovigilance Practices

FDA Office of Orphan Products Development

Case-Control Studies Abdualziz BinSaeed. Case-Control Studies Type of analytic study Unit of observation and analysis: Individual (not group)

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

Signal identification and development I.Ralph Edwards.

Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Alternative Interpretations of the Evidence George A.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.

CCEB October 30 David J. Margolis MD PhD Associate Professor of Dermatology and Epidemiology Center for Clinical Epidemiology and Biostatistics University.

Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.

Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.

Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.

Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

1 BETTER APPROACHES TO MONITORING MEDICAL PRODUCT SAFETY ARE NEEDED.

Chapter 17 Physical Activity Epidemiology Research.

1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.

Risk Assessment Public Meeting - 4/9/03 1 Premarketing Risk Assessment Robert J. Meyer, MD Director, ODE II / OND / CDER Chair of RA Working Group.

Research Activities at The Boston Collaborative Drug Surveillance Program; Boston University School of Public Health Susan Jick Professor of Epidemiology.

Present: Disease Past: Exposure

Mortality and Antithrombotics: Focus on FAERS Repository

Class session 13 Case-control studies

Epidemiology MPH 531 Analytic Epidemiology Case control studies

Objectives: To know the different types and varieties of designs that are commonly used in medical researches. To know the characteristics, advantages.

Presentation transcript:

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of Surveillance, Research & Communication Support Office of Drug Safety FDA

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Multifaceted Challenges Identification of new adverse events Investigation of risk Characterization of context

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events A fundamental goal of post-marketing drug safety programs Must account for many different types of risk Must account for many potentially confounding factors Must account for time course of events

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: What Pre-marketing Safety Data Tell Us Pre-clinical Pharmacology And Toxicology Clinical Pharmacology Clinical Safety Data Open-label Studies Clinical Safety Data Controlled Studies Pre-Marketing Safety Data

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events Pre-marketing Safety Data Market Introduction Post-marketing Period

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events Pre-marketing Safety Data Market Introduction Post-marketing Period ???

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events Pre-marketing Safety Data Market Introduction Post-marketing Period Rare but serious adverse event Aplastic anemia Drug-induced liver injury

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events Pre-marketing Safety Data Market Introduction Post-marketing Period Also common in the population Myocardial infarction

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events Pre-marketing Safety Data Market Introduction Post-marketing Period Also a manifestation of the underlying disease Myocardial infarction

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events Pre-marketing Safety Data Market Introduction Post-marketing Period How do we separate a potential signal from the background?

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events Pre-marketing Safety Data Market Introduction Post-marketing Period Long latency between drug exposure and event

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events Pre-marketing Safety Data Market Introduction Post-marketing Period Multiple Effect Modifiers Drug-drug, drug-disease, drug-herbal, drug-food interactions

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Identification of New Adverse Events Pre-marketing Safety Data Market Introduction Post-marketing Period Proper Identification of Medication Errors Medication Errors

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Investigation of New Adverse Event Risk Pre-marketing Safety Data Market Introduction Post-marketing Period Rare but serious adverse event Intensive case evaluation Look back at pre-marketing safety database

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Investigation of New Adverse Event Risk Pre-marketing Safety Data Market Introduction Post-marketing Period Common in the population OR Manifestation of the underlying disease Intensive case evaluation Look back at pre-marketing safety database Still hard to establish and quantify risk

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Investigation of New Adverse Event Risk Clinical Trial Random Allocation Treatment of Interest Control TreatmentFollow-up Period

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Investigation of New Adverse Event Risk Clinical Trial Random Allocation Treatment of Interest Control TreatmentFollow-up Period

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Investigation of New Adverse Event Risk Clinical Trial Random Allocation Treatment of Interest Control TreatmentFollow-up Period Excess Risk Risk Ratio

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Investigation of New Adverse Event Risk Epidemiological Study - Case-Control Case Ascertainment Control Ascertainment Exposure Ascertainment TreatmentNo Treatment Case Control Odds Ratio

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Investigation of New Adverse Event Risk Epidemiological Study - Cohort Study Start observation Time Relative risk or hazard ratio

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Investigation of New Adverse Event Risk Registry Case-control studies Estimate magnitude of problem Study natural history or survival Persons with disease of interest

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Investigation of New Adverse Event Risk Registry Risk factors for exposure Estimate magnitude of exposure Outcome of exposure Persons with exposure of interest

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Understanding Context - Duration of Exposure Duration of Exposure Risk Initial Exposure Critical period to study

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Understanding Context - Population Exposure Duration of Exposure Number of Persons Exposed

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Understanding Context - Population Exposure Duration of Exposure Number of Persons Exposed

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Understanding Context - Population Exposure Duration of Exposure Number of Persons Exposed

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Understanding Context Duration of Exposure Number of Persons Exposed Duration of Exposure Risk Potential for many adverse events

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Understanding Context: Concomitant Use No concomitant use AB Population database studies can help us understand where risk exists in the population Prevalence of Concomitant Use Prevalence of Adverse Events High level concomitant use AB Low level concomitant use AB

Drug Safety and Risk Management Advisory Committee May 18-19, Post-marketing Drug Safety Risk Assessment: Summary Multifaceted challenges Many ways to explore risk Context can be important